Japan Infectious Disease Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Infection (Bacterial, Viral, Fungal, and Parasitic), By Drug Class (Antibacterial, Vaccines, Antiviral, and Others), and Japan Infectious Disease Therapeutics Market Insights, Industry Trend, Forecasts to 2035.

Japan Infectious Disease Therapeutics Market Insights Forecasts to 2035

• The Japan Infectious Disease Therapeutics Market Size Was Estimated at USD 11024.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 4.62% from 2025 to 2035
• The Japan Infectious Disease Therapeutics Market Size is Expected to Reach USD 18120.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan Infectious Disease Therapeutics market is anticipated to reach USD 18120.3 million by 2035, growing at a CAGR of 4.62% from 2025 to 2035. The Japanese infectious disease therapeutics market is driven by various factors, including the rising incidence of infectious diseases, rising awareness about infectious diseases, advances in diagnostic technologies, and increased government initiatives for disease control.

Market Overview

Infectious disease is a disease produced by pathogenic microorganisms like bacteria, viruses, fungi, or parasites that infect the body. This market focuses on the research, development, production, and distribution of drugs and therapies used to treat infectious diseases within Japan. This includes a wide range of products like antibiotics, antivirals, antifungals, and vaccines. Japan has one of the largest aging populations, and an aging population is more susceptible to infections, which creates the demand for effective therapeutic solutions. The key drivers of the Japanese infectious disease therapeutics market are the growing disease burden of infectious diseases such as TB, hepatitis, and COVID-19, and the level of health expenditure on the treatment of infectious diseases in different regions of Japan. The rising demand for personalized medicines is a key trend in this market. This trend presents an opportunity for the development of more effective treatments for infectious diseases.

Report Coverage

This research report categorizes the market for the Japan infectious disease therapeutics market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the japan infectious disease therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan infectious disease therapeutics market.

Driving Factors

One of the primary drivers is the country’s rapidly aging population, which is more vulnerable to infections due to weakened immunity, thereby increasing the demand for effective therapeutics. The rising prevalence of antimicrobial resistance (AMR) has led to an urgent need for novel antibiotics and advanced treatment approaches. The government initiatives, such as vaccination campaigns, play an important role in market growth. Additionally, technological advancements in rapid diagnostics, immunotherapies and personalized medicines led to the expansion of the market.

Restraining Factors

The high research and development cost, especially for antibiotics, limits the market expansion. Additionally, strengthening regulatory approvals and long drug development timelines further limit the market expansion.

Market Segmentation

The Japan infectious disease therapeutics market share is classified into infection and drug class. 

• The viral segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Japan infectious disease therapeutics market is segmented by infection into bacterial, viral, fungal, and parasitic. Among these, the viral segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the rising prevalence of viral infections such as influenza, HIV, and hepatitis. Additionally, rising urbanization and climate change contribute to the rapid spread of viral diseases.

• The vaccines segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.  

The Japan infectious disease therapeutics market is segmented by drug class into antibacterial, vaccines, antiviral, and others. Among these, the vaccines segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to increasing disease prevalence, growing awareness and strong government immunization programs. Additionally, the rising demand for new and improved vaccines.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan infectious disease therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Hoffmann-La Roche Ltd.
• Janssen Pharmaceutical
• Takeda Pharmaceutical Co. Ltd.
• Astellas Pharma Inc.
• Shionogi & Co., Ltd.
• Meiji Seika Pharma
• Fujifilm Toyama Chemical
• Daiichi Sankyo Co., Ltd.
• Otsuka Holdings Co., Ltd.
• KM Biologics Co., Ltd.
• Kyowa Kirin Co., Ltd.
• Other

Recent Developments

• In June 2025, Shionogi filed to expand ensitrelvir’s use to children aged 6+ in Japan. It also submitted a new 25mg tablet formulation for easier pediatric dosing.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan infectious disease therapeutics market based on the below-mentioned segments:

Japan Infectious Disease Therapeutics Market, By Infection

• Bacterial
• Viral
• Fungal
• Parasitic

Japan Infectious Disease Therapeutics Market, By Drug Class

• Antibacterial
• Vaccines
• Antiviral
• Others